IgA nephropathy primary prevention: Difference between revisions

	IgA nephropathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating IgA nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
IgA nephropathy primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of IgA nephropathy primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on IgA nephropathy primary prevention
CDC on IgA nephropathy primary prevention
IgA nephropathy primary prevention in the news
Blogs on IgA nephropathy primary prevention
Directions to Hospitals Treating IgA nephropathy
Risk calculators and risk factors for IgA nephropathy primary prevention

Latest revision as of 14:46, 25 May 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]

There are no established measures for the primary prevention of IgA nephropathy.

There are no established measures for the primary prevention of IgA nephropathy.

@@ Line 2: / Line 2: @@
 {{IgA nephropathy}}
-{{CMG}}; {{AE}}
+{{CMG}}; {{AE}} {{SH}}
 ==Overview==
-There are no established measures for the primary prevention of [disease name].
+There are no established measures for the primary prevention of IgA nephropathy.
-OR
-There are no available vaccines against [disease name].
-OR
-Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
-OR
-[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
 ==Primary Prevention==
-*There are no established measures for the primary prevention of [disease name].
+*There are no established measures for the primary prevention of IgA nephropathy.
-*There are no available vaccines against [disease name].
-OR
-*Effective measures for the primary prevention of [disease name] include:
-**[Measure1]
-**[Measure2]
-**[Measure3]
-OR
-*[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include:
-**[Strategy 1]
-**[Strategy 2]
-**[Strategy 3]
 ==References==